Опыт применения генно-инженерного биологического препарата в лечении пациентки с болезнью Шегрена

Abstract

Sjogren’s syndrome (SS) a chronic slowly progressive autoimmune disorder caused by the production of anti-nuclear antibodies and B cell hyperactivity. This disease affects exo-crine glands and involves a number of other organs and systems. In SS with systemic manifes-tations that is resistant to standard corticosteroids and basic anti-inflammatory treatment, en-gineered biological therapies are recommended. B cells having an important pathogenic role in SS are the most promising therapeutic target. Multiple comorbidities should not be considered the contraindications to anti-B-cell therapy. The paper addresses a case study of SS in a 68-year-old woman and authors’ experience with engineered biological therapy (rituximab). Rituximab treatment resulted in the significant clinical improvement as demonstrated by the reduction in dry mouth and dry eye symptoms, the improvements in exercise tolerance, ab-dominal pain relief, and improved dyspnea. Laboratory tests also showed the reduction in the acute phase and immunological activity of SS.KEYWORDS: Sjogren’s syndrome, autoimmune disorder, engineered biological therapy, anti-B-cell therapy, dryness, xerostomia, xerophthalmia, rituximab.FOR CITATION: Svintsitskaya I.S., Volkov K.Yu., Tyrenko V.V., Sopova D.I. Experience with an engineered biological therapy for Sjogren’s syndrome. Russian Medical Inquiry. 2020;4(8):529–534. DOI: 10.32364/2587-6821-2020-4-8-529-534.